Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

19.03 -0.63 (-3.20%)
Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,411,840
Open 19.70
Bid (Size) 19.00 (2)
Ask (Size) 19.52 (1)
Prev. Close 19.66
Today's Range 18.95 - 19.73
52wk Range 10.84 - 23.10
Shares Outstanding N/A
Dividend Yield 5.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and... 
Via Talk Markets
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2... 
Via Benzinga

Performance

YTD
+29.37%
+29.37%
1 Month
-17.37%
-17.37%
3 Month
-7.76%
-7.76%
6 Month
+3.14%
+3.14%
1 Year
+10.32%
+10.32%

More News

Read More
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
3 Cheap High Dividend Stocks For Passive Income
Via Talk Markets
High Dividend 50: Organon & Co.
Via Talk Markets
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Via Benzinga
Organon Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
From Organon & Co.
Via Business Wire
OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Organon Reports Results for the Second Quarter Ended June 30, 2024
From Organon & Co.
Via Business Wire
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
Via Benzinga
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
Via The Motley Fool
Topics ETFs
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Via InvestorPlace
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Beats On Q1, Women's Health Leads the Charge
Via Benzinga
OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.